Kit Simpson to Tissue Plasminogen Activator
This is a "connection" page, showing publications Kit Simpson has written about Tissue Plasminogen Activator.
Connection Strength
0.796
-
Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
Score: 0.466
-
Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial. Stroke. 2014 Jun; 45(6):1791-8.
Score: 0.095
-
Letter by Hill et al regarding article, "A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke". Stroke. 2011 Dec; 42(12):e641-2; author reply e643.
Score: 0.079
-
Hospital care for patients experiencing weekend vs weekday stroke: a comparison of quality and aggressiveness of care. Arch Neurol. 2010 Jan; 67(1):39-44.
Score: 0.070
-
Population Health Indicators Associated with a Statewide Telestroke Program. Telemed J E Health. 2020 09; 26(9):1126-1133.
Score: 0.035
-
Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data. Stroke. 2015 Dec; 46(12):3416-22.
Score: 0.026
-
Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
Score: 0.025